CBDV isolate

  • CBDV isolate


Purity >99%

CBDV (cannabidivarin) is a phytocannabinoid that occurs naturally in Cannabis plant, yet only several strains have appreciable amounts of CBDV.

Our synthetic pathway overcomes main difficulties associated with tedious extraction of CBDV from natural sources and allows us to meet the demand for this rare cannabinoid on any scale you’d be interested in.

Contact UsBook a CallGet a sample

If you want to join our satisfied clients – be sure to contact us or book a call!



Origin Semi-synthetic
Appearance White-off powder
Consistency Solid
Purity >99%

CBDV Isolate

Next up on our introduction to minor cannabinoids, is Cannabidivarin (CBDV). So, what is CBDV cannabinoid?

In simple terms, CBDV is another part of the cannabis plant, a compound found within the genetic make up.

To us at Sanobiotec, CBDV is so much more than just another phytocannabinoid found within the cannabis plant though.

CBDV cannabinoid harbours plenty of powerful potential, especially when it comes to preventing epileptic seizures. It’s always a good idea to be cautious with things like this, so as to not raise expectations unrealistically, but on the other hand, when all the evidence is suggesting that CBDV is incredibly beneficial in the therapeutic prevention and treatment of seizures, it’s hard to not get a little excited.

Structurally and functionally, CBDV cannabinoid is very similar to the major cannabinoid cannabidiol (CBD) but unlike CBD, CBDV is understood to modulate its primary physiological effects independently of the endocannabinoid receptors CB1 and CB2.

It’s much less well known too, and that’s understandable, given the fact that it occurs in much lower percentages than the major cannabinoid it is similar to.

Is CBDV isolate another promising rare compound then? We certainly think so.

So, where do we get it from? Where CBDV isolate can it be found?

Primarily sourced from Cannabis sativa strains found in Asia and Africa, higher concentrations of CBDV are found in strains of cannabis plant with low THC and higher CBD content.

Typically, higher percentages of THC would be considered to have more ‘trippy’ effects, making strains like this more popular for recreational users. That’s not what we’re talking about here though. We’re looking at the therapeutic benefits of minor cannabinoids.

CBDV’s potential may not be limited to only a few benefits. Further research and development provides the opportunity to explore the benefits of this minor cannabinoid. For a start, the receptor TRPV1 is also known to regulate pain transmission and modulation, which raises the question as to whether CBDV could be used to ameliorate neuropathic pain.

This is quite exciting to Sanobiotec, and so is the fact that preliminary evidence suggests that CBDV displays anti-inflammatory effects as it binds to the TRPA1 receptor.


Recent Relevant Research

It’s all getting a bit technical, so what does all this mean?
A number of things, but these early findings have kick started a number of preclinical studies into CBDV, to explore its potential for treating things like:

  • Inflammatory bowel disease
  • Ulcerative colitis
  • Duchenne muscular dystrophy
  • Crohn’s disease

Interestingly, CBDV may also modulate anti nausea effects by acting as an antagonist to CB1 receptors.
How do we find out whether any or all of the above can actually make a difference to people’s lives?
It’s all down to research and development. Recent research and development into CBDV has looked to explore its applications and effectiveness for:

  • ASD
  • Epilepsy
  • The brain and peripheral nervous system
  • Nausea
  • Seizures
  • Immunity
This is a summary of the research interests for each cannabinoid being discussed. These statements have not been evaluated by regulatory bodies such as Food and Drug Administration. This ingredient is not intended to diagnose, treat, cure or prevent any disease. Sanobiotec has provided this summary solely to provide the reader with information on the types of studies being conducted on cannabinoids.
1. Amada N. et al. Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. PeerJ. 2013 Nov 21;1:e214. doi: 10.7717/peerj.214. eCollection 2013.
2. Bisogno T. et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003 Nov 10;163(3):463-8. doi: 10.1083/jcb.200305129.
3. Capasso A: Do Cannabinoids Confer Neuroprotection Against Epilepsy? An Overview. Open Neurol J. 2017 Dec 18;11:61-73. doi: 10.2174/1874205X01711010061. eCollection 2017.
4. De Petrocellis L. et al: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011 Aug;163(7):1479-94. doi: 10.1111/j.1476-5381.2010.01166.x.
5. Gaston TE, Friedman D: Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav. 2017 May;70(Pt B):313-318. doi: 10.1016/j.yebeh.2016.11.016. Epub 2017 Jan 10.
6. Hill AJ. et al. Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol. 2012 Dec;167(8):1629-42. doi: 10.1111/j.1476-5381.2012.02207.x.
7. Iannotti FA et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci. 2014 Nov 19;5(11):1131-41. doi: 10.1021/cn5000524. 2014 Jul 29.
8. Sharma P. et al. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012 Fall;7(4):149-56.
9. Morano A. et al. Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin. Epilepsia Open. 2016 Sep 19;1(3-4):145-151. doi: 10.1002/epi4.12015. eCollection 2016 Dec.
10. Rock EM et al. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. Br J Pharmacol. 2013;170(3):671-678. doi:10.1111/bph.12322
11. Ruzic Zecevic D. et al. Investigational cannabinoids in seizure disorders, what have we learned thus far? Expert Opin Investig Drugs. 2018 Jun 6:1-7. doi: 10.1080/13543784.2018.1482275.